Recursion Pharmaceuticals Inc (RXRX)

NASDAQ

Currency in USD

RXRX Pro Research

3.78

+0.18(+5.00%)

Closed·17/04

After Hours

3.71-0.07(-1.85%)

·01:44:31

Fair Value

Unlock Value

Day's Range

3.71

3.88

52 wk Range

2.80

7.18

RXRX Income Statement

Assess the Recursion Pharmaceuticals income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the RXRX net worth.

Period Ending:

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

aa.aa

58.84

74.68

Total Revenues Growth

aa.aa

+32%

+26.92%

Cost Of Revenues

aa.aa

359.66

546.22

Gross Profit

aa.aa

-300.82

-471.54

Gross Profit Growth

aa.aa

-25.74%

-56.75%

Gross Profit Margin %

aa.aa

-511.26%

-631.41%

Other Operating Expenses, Total

aa.aa

178.18

176.59

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+60.78%	-0.9%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	178.18	176.59
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-

Operating Income

aa.aa

-479

-648.13

Operating Income Growth

aa.aa

-36.83%

-35.31%

EBIT Margin %

aa.aa

-814.09%

-867.87%

Net Interest Expenses

aa.aa

14.19

20.98

Net Interest Expenses Growth

aa.aa

-25.41%

+47.88%

Interest Expense, Total

aa.aa

-1.57

-1.81

Interest And Investment Income

aa.aa

15.76

22.79

Other Non Operating Expenses, Total

aa.aa

0.03

-17.74

EBT, Excl. Unusual Items

aa.aa

-464.79

-644.9

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

EBT, Incl. Unusual Items

aa.aa

-464.79

-644.9

EBT, Incl. Unusual Items Growth

aa.aa

-39.94%

-38.75%

EBT, Incl. Unusual Items Margin

aa.aa

-789.93%

-863.53%

Income Tax Expense

aa.aa

-1.13

-0.14

Net Income to Company

aa.aa

-463.66

-644.76

Minority Interest

aa.aa

Net Income

aa.aa

-463.66

-644.76

Net Income Growth

aa.aa

-41.33%

-39.06%

Net Income Margin %

aa.aa

-788.02%

-863.35%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-463.66

-644.76

Basic EPS - Continuing Operations

aa.aa

-1.69

-1.44

Basic EPS - Continuing Operations Growth

aa.aa

-7.13%

+14.78%

Diluted EPS - Continuing Operations

aa.aa

-1.69

-1.44

Diluted EPS - Continuing Operations Growth

aa.aa

-7.13%

+14.78%

Basic Weighted Average Shares Outstanding

aa.aa

274.21

447.45

Diluted Weighted Average Shares Outstanding

aa.aa

274.21

447.45

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-442.51

-564.43

EBITDA Growth

aa.aa

-35.88%

-27.55%

EBITDA Margin %

aa.aa

-752.07%

-755.79%

EBIT

aa.aa

-479

-648.13

* In Millions of USD (except for per share items)

FAQ

What was Recursion Pharmaceuticals’s revenue at year end?

At the end of the last reported fiscal year, Recursion Pharmaceuticals (RXRX) recorded total revenue of 74.68 million USD.

How much revenue did Recursion Pharmaceuticals report in the most recent quarter?

In its most recent quarterly earnings report, Recursion Pharmaceuticals posted revenue of 35.54 million USD.

What was Recursion Pharmaceuticals’s net income for the year?

For the full year, Recursion Pharmaceuticals reported net income of -644.76 million USD.

How much net income did Recursion Pharmaceuticals post in the last quarter?

In the most recent quarter, Recursion Pharmaceuticals (RXRX) posted net income of -108.12 million USD.

What was Recursion Pharmaceuticals’s gross profit for the year?

Gross profit for the year was reported at -471.54 million USD.

How much gross profit did Recursion Pharmaceuticals generate last quarter?

Recursion Pharmaceuticals recorded gross profit of -74.68 million USD in its latest quarterly report.

What was Recursion Pharmaceuticals’s annual operating income?

For the full year, Recursion Pharmaceuticals (RXRX) reported operating income of -648.13 million USD.

What was Recursion Pharmaceuticals’s operating income last quarter?

Quarterly operating income was -116.85 million USD.

What was Recursion Pharmaceuticals’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -97.37 million USD.

What was the quarter-over-quarter change in EBITDA for Recursion Pharmaceuticals?

EBITDA changed by 35.58% million USD compared to the last quarter.

What is Recursion Pharmaceuticals’s most recent gross profit margin?

The latest reported gross profit margin for Recursion Pharmaceuticals (RXRX) is -210.13% million USD.

What is Recursion Pharmaceuticals’s most recent net income margin?

Net income margin based on recent financials is -304.24% million USD.

What is Recursion Pharmaceuticals’s most recent EBIT margin?

Recursion Pharmaceuticals reported an EBIT margin of -328.80% million USD based on current figures.

How did Recursion Pharmaceuticals’s revenue change compared to the previous quarter?

Revenue changed by 586.72% million USD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Recursion Pharmaceuticals?

In the latest quarter, gross profit changed by 42.81% million USD from the previous quarter.

S&P/TSX

34,346.29

+294.06

+0.86%

S&P/TSX 60

1,995.50

+16.50

+0.83%

US 30

49,052.50

-395.4

-0.80%

US 500

7,074.70

-51.3

-0.72%

S&P 500 VIX

17.48

-0.46

-2.56%

DAX

24,702.24

+547.77

+2.27%

Dollar Index

98.19

+0.292

+0.30%

Market Movers

Name	Last	Chg. %	Vol.
Canadian Natural	58.81	-7.34%	21.92M
Enbridge	72.09	+0.14%	8.26M
TC Energy	82.92	+0.18%	7.75M
Suncor Energy	83.69	-4.21%	6.60M
RBC	244.23	+1.30%	5.33M
Toronto Dominion Bank	144.17	+1.19%	3.90M
Canadian Imperial Bank	149.43	+1.40%	2.68M

Name	Last	Chg. %	Vol.
PeakBirch Logic	0.030	+500.00%	1.32K
New Leaf Ventures	0.05	+400.00%	666.82K
Icarus Capital	0.05	+150.00%	1.00K
Irwin Naturals	0.30	+150.00%	3.24K
Green Scientific Labs Holdings	0.06	+120.00%	15.00K
Digicann Ventures	0.010	+100.00%	31.00K
ePlay Digital	0.010	+100.00%	7.00K

Name	Last	Chg. %	Vol.
Metamaterial	0.25	-92.86%	0.00
New Frontier Ventures	0.030	-68.42%	13.00K
Moss Genomics	0.03	-57.14%	2.00K
MX Gold Corp	0.0200	-55.56%	5.00K
Molecule Holdings	0.005	-50.00%	20.11K
Aurora Solar Technologies	0.0050	-50.00%	24.30K
CAT Strategic	0.0050	-50.00%	1.30K

Trending Stocks

Name	Last	Chg. %	Vol.
Canadian Natural	58.81	-7.34%	21.92M
Celestica Inc.	542.89	+3.48%	463.96K
Keel Infra	3.96	+5.88%	4.47M
Cenovus Energy Inc	33.55	-5.49%	9.80M
Quantum eMotion	4.0000	+11.42%	763.21K

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaa A Aaaa	5.33	+58.80%	8.46
Aaaa Aaa	104.47	+46.34%	152.88
Aaaa Aaaaa	47.25	+43.82%	67.95
Aaaa Aaaa	10.87	+43.51%	15.60
Aaaaaaaa A	6.86	+42.02%	9.74
Aaaa Aa A	116.42	+40.63%	163.72
Aaa Aaaaa Aaa	3.46	+38.70%	4.80

Name	Last	Upside	Fair Value
Aaaaaa A Aaaa	5.33	+58.80%	8.46
Aaaa Aaa	104.47	+46.34%	152.88
Aaaa Aaaaa	47.25	+43.82%	67.95
Aaaa Aaaa	10.87	+43.51%	15.60
Aaaaaaaa A	6.86	+42.02%	9.74
Aaaa Aa A	116.42	+40.63%	163.72
Aaa Aaaaa Aaa	3.46	+38.70%	4.80

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Recursion Pharmaceuticals Inc (RXRX)

RXRX Income Statement

FAQ

What was Recursion Pharmaceuticals’s revenue at year end?

How much revenue did Recursion Pharmaceuticals report in the most recent quarter?

What was Recursion Pharmaceuticals’s net income for the year?

How much net income did Recursion Pharmaceuticals post in the last quarter?

What was Recursion Pharmaceuticals’s gross profit for the year?

How much gross profit did Recursion Pharmaceuticals generate last quarter?

What was Recursion Pharmaceuticals’s annual operating income?

What was Recursion Pharmaceuticals’s operating income last quarter?

What was Recursion Pharmaceuticals’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Recursion Pharmaceuticals?

What is Recursion Pharmaceuticals’s most recent gross profit margin?

What is Recursion Pharmaceuticals’s most recent net income margin?

What is Recursion Pharmaceuticals’s most recent EBIT margin?

How did Recursion Pharmaceuticals’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for Recursion Pharmaceuticals?

Trending Stocks